Christopher T. Rentsch

Jan 6, 2025 | onlinelibrary.wiley.com | Marleen Bokern |Christopher T. Rentsch |Jennifer K Quint |Jacob N. Hunnicutt

COVID-19 outcomes may have been at risk of misclassification early during the COVID-19 pandemic. No pharmacoepidemiological studies have evaluated the impact of such misclassification on their findings. We used several forms of quantitative bias analysis to adjust for outcome misclassification in an analysis of inhaled corticosteroids and COVID-19 hospitalisation and death. We found that all methods shifted effect estimates away from the null, albeit to a limited extent.

Nov 27, 2024 | onlinelibrary.wiley.com | Elizabeth T. Mansi |Christopher T. Rentsch |Richard Bourne |Bruce Guthrie

One in 20 adults hospitalised for critical illness were prescribed a new benzodiazepine or z-drug within 90 days of hospital discharge by their primary care provider. Almost half of those prescribed received more than one prescription. Zopiclone was the most common drug prescribed (50%) followed by diazepam (19%). Patient-level factors associated with benzodiazepine or z-drug prescription included a history of insomnia, anxiety or depression and recent opioid prescription.

Nov 19, 2024 | nature.com | Ruth Costello |Emily Herrett |Amir Mehrkar |Laurie Tomlinson |Christopher T. Rentsch

AbstractBiological evidence suggests ursodeoxycholic acid (UDCA)—a common treatment of cholestatic liver disease—may prevent severe COVID-19 outcomes. We aimed to compare the hazard of COVID-19 hospitalisation or death between UDCA users versus non-users in a population with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC).

Aug 14, 2024 | medrxiv.org | Marleen Bokern |Christopher T. Rentsch |Jennifer K Quint |Jacob N. Hunnicutt

MPB is funded by a GSK PhD studentship to investigate the application of quantitative bias analysis in observational studies of COVID-19. IJD has unrestricted grants from and shares in GSK. AS is employed by LSHTM on a fellowship funded by GSK. JH was employed by GSK and owned stock in GSK during the conduct of this work. CTR and JQ report no conflicts of interest.

May 7, 2024 | nature.com | Zeal Jinwala |Emily E. Hartwell |Mirko Pavicic |Kyle Sullivan |Ke Xu |Daniel Jacobson | +5 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-02839-5, published online 1 March 2024In the version of the article initially published, the pipeline for the cross-ancestry meta-analysis did not accurately code some SNPs such that they were not combined despite being the same polymorphism. To fix this, we correctly annotated the rsIDs for the summary statistics from each ancestry and meta-analyzed them based on the unique rsID for each polymorphism.